The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes ... that there’s no longer a shortage of weight-loss drugs that had allowed for alternatives ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a ...

Attorney General Dave Sunday is warning Pennsylvanians to make sure they're using licensed pharmacies for GLP-1 drugs amid a growing counterfeit market.

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors.

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Teal Health's test would give an alternative to in-office pap smears. Other pharma and health industry news covers a new CEO at the American Medical Association; robots at Walgreens; a startup from ...